Business Wire - November 14, 2001
Calypte has worked closely with Planned Parenthood in San Jose over the past several months to provide the required support for the laboratory to complete its evaluation of Calypte's urine screening and supplemental tests for HIV-1 antibodies. The State of California has licensing requirements for all California laboratories that perform any type of HIV testing. Planned Parenthood has successfully completed requirements for licensure for Calypte's urine HIV testing in the State of California. Planned Parenthood anticipates a very positive response to offering the option of urine HIV testing. The laboratory currently performs more than 12,000 HIV tests each year. Additionally, Planned Parenthood indicates that with the availability of testing systems for Chlamydia, Gonorrhea and HIV on urine, it can offer a comprehensive testing panel for the most common sexually transmitted diseases (STDs) on one urine specimen. Among the several Planned Parenthood clinics served by the laboratory at Planned Parenthood Mar Monte are the Planned Parenthood clinics on the Alameda and in Blossom Hill, both of which are in the San Jose area.
According to Nancy Katz, Calypte's president & CEO, "Planned Parenthood's decision to offer the urine HIV test represents a milestone in Calypte's combined objectives of marketing our non-invasive urine HIV testing technology in the health service market and participating in the fight against AIDS. I am certain that Planned Parenthood will see an increase in voluntary testing for HIV that is consistent with the CDC's (Centers for Disease Control) initiative to increase the number of people who are aware of their HIV status through voluntary testing. Our experience with other healthcare providers that have chosen urine as an alternative to blood testing for HIV is that more people will be voluntarily tested using urine because it is simple to collect, does not require the invasive process of blood drawing and provides equivalent accuracy to blood testing when coupled with urine western blot testing. The addition of urine HIV testing as an option by Planned Parenthood is a clear indication of their commitment to their constituency."
Planned Parenthood Mar Monte began offering urine HIV testing using Calypte's HIV-1 urine antibody tests on Nov. 12, 2001. This relationship with Planned Parenthood Mar Monte has raised interest with other Planned Parenthood locations for urine testing for STDs. Calypte is currently working closely with another northern California Planned Parenthood group and is following up with groups in the Mid-West that have expressed interest in Calypte's urine test for HIV.
Calypte Biomedical Corporation headquartered in Alameda is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners.
Statements in this press release that are not historical facts are forward-looking statements, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2000 and its subsequent filings with the SEC.
011114
BW011114
Copyright © 2001 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .